Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition
You may also be interested in...
French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.
Sandoz has a monopoly on the generic enoxaparin market for now, but Teva insists its ANDA is progressing at FDA.
Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.